Retatrutide FDA approval status

Is retatrutide FDA approved?

No. In October 2026 Lilly wrote that retatrutide "has not been approved by FDA or any regulatory organization anywhere in the world."^[1] Its third-quarter 2026 earnings report did not list a submission.^[4]

The FDA also says that "retatrutide and cagrilintide cannot be used in compounding under federal law", so compounding pharmacies cannot legally make it.^[10]

When will retatrutide be available?

Not before an FDA approval decision, and there is no retatrutide release date yet. In July 2026 Lilly said it was completing the manufacturing part of the application and "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval".^[2] The FDA's review then has to run its course, so an approval decision would come after that submission. Lilly has not published an expected approval date. The FDA's own review goals, explained below, put a decision roughly 8 to 12 months after submission.

Did Eli Lilly delay the retatrutide approval filing until early 2027?

Lilly's filing is now planned for the first quarter of 2027, later than the 2026 date that had been widely expected. On July 23, 2026 Lilly said it was completing the chemistry, manufacturing and controls (CMC) package and "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval."^[2] News coverage described this as later than the 2026 filing that had been expected, and reported that Lilly needed more time to gather and verify manufacturing and quality-control data.^[3] Lilly's own release does not use the word "delay". Its October 2026 quarterly report still listed no submission.^[4]

A separate legal question runs alongside the filing: Lilly is challenging the FDA's 2024 decision to classify retatrutide as a drug rather than a biologic. A federal court sent part of that decision back to the FDA in September 2025.^[9] Lilly still plans to file a biologics license application. Details are on Eli Lilly retatrutide lawsuits.

What happens after Lilly files: the FDA review clock

Once an application for a new medicine is filed, the FDA aims to act within 10 months under a standard review, or 6 months under a priority review. Both clocks start at the "60-day filing date", about two months after submission. These goals apply to new-molecule drug applications and original biologics applications alike, so they hold whichever way the classification dispute ends.^[5]

The last column is our arithmetic, not a Lilly or FDA date. Lilly has not said it has priority review, the goals are targets for 90% of applications rather than all of them, and a decision can also be a rejection (a "complete response") rather than an approval.^[5]

Timeline so far

Sources for the timeline: Lilly announcements, the trial publications and ClinicalTrials.gov.^{[11][12][2][1][13][14][6][8][15]}

Can anyone get it before approval?

Only through a clinical trial or a pre-approval access program. ClinicalTrials.gov lists an expanded-access program (NCT07629401) for single patients, requested by a physician. It is limited to people with a BMI of 35 or more, at least two serious obesity-related complications, no response to approved treatments, and no access to a trial.^[7] See Eli Lilly retatrutide early access and how to get retatrutide.

What this means for price

Without approval there is no official price. See retatrutide cost for what Lilly charges for its approved drug Zepbound today, and retatrutide results for the trial data the FDA will review.

Trials still running

TRIUMPH-5 (retatrutide vs tirzepatide), long-term weight-maintenance and back-pain trials, and a 10,000-person cardiovascular and kidney outcomes trial are still active. ClinicalTrials.gov lists their primary completion dates between 2027 and 2029.^[6]